<DOC>
	<DOCNO>NCT01063946</DOCNO>
	<brief_summary>Primary Objectives : - To determine excretion balance systemic exposure radioactivity intravenous infusion [ 14C ] -AVE8062 humans - To determine pharmacokinetics AVE8062 RPR258063 contribution overall exposure - To collect sample determine metabolic pathway AVE8062 identify chemical structure main metabolite Secondary Objective : - To assess safety profile drug</brief_summary>
	<brief_title>A Study Investigate Disposition Radio-labeled AVE8062 Compound Administered 30-minute IV Infusion Patients With Advanced Solid Tumor</brief_title>
	<detailed_description>The duration study patient include approximately 4 week screen phase prior first infusion study drug , 21-day study treatment cycle end treatment visit . The patient continue treatment disease progression , unacceptable toxicity , patient 's refusal treatment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Patients advance neoplastic disease become refractory conventional treatment standard therapy exist . Age = &gt; 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Adequate hematological , hepatic renal function Exclusion criterion : Poor metabolizers CYP2C19 , CYP2C9 , CYP2D6 polymorphic UGTs exclude study The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>